title: A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting.
abstract: New-onset diabetes after transplantation (NODAT) is frequently encountered after kidney transplant. In the present study, we retrospectively evaluated the safety and efficacy of linagliptin monotherapy in 21 renal transplant recipients in a real world setting. We found linagliptin monotherapy is effective for glycemic control in NODAT, even on glucocorticoids and standard dose of tacrolimus. There was no alteration of tacrolimus drug levels or estimated glomerular filtration rate (eGFR) and minimal side effects, including weight gain and hypoglycemia. Well-designed, powered randomized controlled of antiglycemic agents in NODAT are needed.
authors.affiliation: Department of Endocrinology, Rabindranath Tagore International Institute of Cardiac Sciences and KPC Medical College and Hospital, Kolkata, West Bengal, India.
authors.forename: Debmalya
authors.initials: D
authors.lastname: Sanyal
authors.forename: Soumava
authors.initials: S
authors.lastname: Gupta
authors.forename: Pratik
authors.initials: P
authors.lastname: Das
keywords: Linagliptin; new-onset diabetes after transplantation; renal transplant